<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931567</url>
  </required_header>
  <id_info>
    <org_study_id>01-APR-07</org_study_id>
    <nct_id>NCT00931567</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing</brief_title>
  <official_title>Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical, multicentric, randomised open trial. The objective is to evaluate&#xD;
      the efficiency, in terms of wound healing speed, of peroperative application of autologous&#xD;
      platelets gel versus standardized wound dressing. The wound Healing model used in this study&#xD;
      is the &quot; open palm &quot; surgical treatment of Dupuytren's disease.&#xD;
&#xD;
      Dupuytren's disease is a fibroproliferative disease of the palmar and digital fascia of the&#xD;
      hand that may lead to a fixed flexion contracture of the fingers.&#xD;
&#xD;
      The main indication for surgery is the loss of finger extension. In some cases of palmar&#xD;
      Dupuytren's disease the surgical removal of diseased tissues may lead to a cutaneous loss of&#xD;
      substance (&quot; open palm technique &quot;). This loss of substance is treated using vaseline&#xD;
      dressing and the wound healing is obtained in 4 weeks.&#xD;
&#xD;
      Autologous platelets gel (Platelet Rich Fibrin) is obtained from the patient's own blood.&#xD;
      Some recent studies have shown that it speeds up the wound healing and enhances the quality&#xD;
      of the scar.&#xD;
&#xD;
      PRF belongs to a new generation of autologous platelet gel that are easily obtained after&#xD;
      centrifugation of patient's own blood.&#xD;
&#xD;
      The Platelet Rich Fibrin (PRF) contains many wound healing factors : Three pro inflammatory&#xD;
      cytokines ( IL1,IL6, TNF-alpha) , one anti-inflammatory cytokine (IL4) and a growth factor&#xD;
      (VEGF).&#xD;
&#xD;
      The study will be running on 60 days, starting from the operation day. The wound healing&#xD;
      evaluation will be achieved at day1, day2, day7, day14, day 21 day 28 and day 60.&#xD;
&#xD;
      The inclusion criteria are : age over 18, Dupuytren's disease with an indication of surgical&#xD;
      treatment using the open palm technique, patients having signed the agreement form.&#xD;
&#xD;
      80 patients will be included in the study and divided into 2 groups . The first group of&#xD;
      patients will receive PRF and the other group will receive vaseline dressings.&#xD;
&#xD;
      The speed and the quality of wound healing will be compared.We will also compare the number&#xD;
      of patients with a complete wound healing at day 21 . Moreover,we will evaluate the pain&#xD;
      during the dressings' change and the bleeding of the palmar wound.&#xD;
&#xD;
      For the wound healing speed , a difference of 7 days between the two groups will be&#xD;
      considered as statistically significant.&#xD;
&#xD;
      Statistical analysis will be achieved using Chi2 test and Logrank test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main evaluation criteria :&#xD;
&#xD;
      Time duration between the operation and the complete wound healing. The wound healing is&#xD;
      considered complete when the skin is closed and when the patient do not need to have&#xD;
      dressings. A picture of the wound at the end of the wound healing process is taken for each&#xD;
      patient.&#xD;
&#xD;
      Secondary criteria of evaluation :&#xD;
&#xD;
      At day 1, day7, day 14, day 21 and day 28 two data will be collected :&#xD;
&#xD;
        -  The pain during the dressings' change using a visual scale going from 0 (no pain) to 10&#xD;
           (very painful).&#xD;
&#xD;
        -  The bleeding (and &quot;exudate&quot;) of the wound which can be absent, low, moderate or&#xD;
           abundant.&#xD;
&#xD;
      The investigators will collect all the side effects described by the patients for each wound&#xD;
      healing technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time duration between the operation and the complete wound healing.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-The pain during the dressings' change using a visual scale going from 0 to 10. -The bleeding of the wound.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Dupuytren's Contracture</condition>
  <arm_group>
    <arm_group_label>Vaselitulle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>after surgery, the loss of substance is treated using vaseline dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous platelets gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after surgery, the loss of substance is treated with Autologous platelets gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous platelets gel</intervention_name>
    <description>Application of autologous platelets gel (Platelet Rich Fibrin) after the &quot; open palm &quot; surgical treatment of Dupuytren's disease.</description>
    <arm_group_label>Autologous platelets gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vaselitulle</intervention_name>
    <description>application of standardized wound dressing after the &quot; open palm &quot; surgical treatment of Dupuytren's disease.</description>
    <arm_group_label>Vaselitulle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Patient with Dupuytren's disease with an indication of surgical treatment using the&#xD;
             open palm technique.&#xD;
&#xD;
          -  Agreement form signed&#xD;
&#xD;
          -  patient affiliated to the national health system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients allergic to one of the components of the dressings used in this study.&#xD;
&#xD;
          -  Patients with insulin-requiring diabetes&#xD;
&#xD;
          -  Patients sustaining anti-cancer treatment.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Patients included in another study.&#xD;
&#xD;
          -  Patients who cannot come to the follow up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 05</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice Hôpital de Cimiez</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>March 19, 2012</last_update_submitted>
  <last_update_submitted_qc>March 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

